KLRD1 and colorectal carcinoma: Although metastatic microsatellite-stable CRC patients do not respond to therapies that involve PD-1/PD-L1 blockade [257], a first phase I clinical trial studying an antibody against PD-1 (durvalumab) in combination with an antibody targeting CD94/NGK2a (monalizumab) is ongoing.